Tu2018 - Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease
暂无分享,去创建一个
W. Reinisch | B. Jang | B. Ye | S. Ben-Horin | M. R. Kim | A. Puķītis | A. Lahat | S. Y. Lee | V. Borzan | Sang Joon Lee | Y. Mostovoy | S. Schreiber | Osipenko Mf